A federal judge has ordered CVS Caremark to pay almost $290 million in damages and penalties after a whistleblower proved the ...

CVS Health (CVS) stock in focus as its pharmacy benefit manager CVS Caremark faces $289.9M in damages and penalties for ...

Whistleblower Sarah Behnke's lawsuit leads to a $290 million judgment against CVS Caremark for overcharging Medicare on ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Notably, the case came from a whistleblower lawsuit filed by Sarah Behnke, a former Medicare Part D actuary at Aetna, who ...

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

CVS Health hiked its 2025 forecast above Wall Street’s expectations after improving Medicare benefits contributed to a better-than-expected first quarter.

Overall, CVS Health booked adjusted earnings of $2.25 per share as the company’s profit soared 60% to $1.78 billion in the year’s first quarter. Total revenue climbed 7% to $94.59 billion.